Bio-Matrix Scientific Group Inc (BMSN) 0.0001 $BMSN
Regenerative Medicine - Global Trends, Estimates and Forecasts, 2013-2019
M2 - Thu Apr 23, 9:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z5h992/regenerative) has announced the addition of the "Regenerative Medicine - Global Trends, Estimates and Forecasts, 2013-2019" report to their offering. Global Regenerative Medicine market is estimated to reach US$24.7 billion by 2017. Regenerative Medicine in Orthopedics market is projected to reach US$10.3 billion by 2017, growing at a CAGR of 12.2% for the analysis period 2013-2019 respectively. Skin/Integumentary and Urology together account for approximately 25.97% (2016) of the market are expected to support the Regenerative Medicine Industry going forward. Geographical analysis for Regenerative Medicine in Cardiology shows that the highest Compounded Annual Growth Rate (CAGR) of 18.1% is anticipated from Asia-Pacific region during the analysis period 2013-2019. The report Regenerative Medicine - Global Trends, Estimates and Forecasts, 2013-2019' reviews the latest trends in regenerative medicine with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for healthcare sector investments. The study reveals profitable investment strategies for market start-ups, pharmaceutical/biotechnology companies, laboratories, Contract/Clinical/Commercial Research Organizations (CROs), government/academic organizations, consulting firms, database buyers and many more in preferred locations. Regenerative Medicine - Segmentation - Therapeutic Area - Orthopedics - Skin/Integumentary - Cardiology - Neurology - Urology - Other - Biological Substitutes - Cells and Biomaterials - Biomolecules - Manufacturing Factors and - Other Companies Mentioned The Americas - Cell2B (USA) - Angiocrine Bioscience (USA) - Platelet Biogenesis (USA) - Biomatrica, Inc (USA) - Athersys, Inc. (USA) - Cellular Dynamics International, Inc. (USA) - Tengion Inc (USA) - Vericel Corporation (USA) - Wright Medical Technology (USA) - Tissuegene, Inc. (USA) - Shire Regenerative Medicine (USA) - Regen Biopharma (Bio-Matrix Scientific Group) (USA) - Dsm Biomedical (USA) - Harvard Apparatus Regenerative Technology (USA) Europe - Cellserve Gmbh (Germany) - Trakcel Ltd (United Kingdom) - Crispr Therapeutics (Switzerland) Asia-Pacific - Cytori Therapeutics Inc (Japan) - Cyfuse Biomedical Kk (Japan) - Regenovo Biotechnology (China) - Cynata Therapeutics Limited (Australia) For more information visit http://www.researchandmarkets.com/research/z5...generative
VCEL: 2.12 (-0.01), ICEL: 16.55 (+0.03), CYTX: 1.99 (-0.02), ATHX: 2.13 (-0.02)
Regen BioPharma Scheduled to Make Presentation at American Society for Hematology's 56th Annual Meeting in San Francisco December 6th - 9th
Marketwired - Mon Dec 01, 7:30AM CST
Regen BioPharma (OTCBB: RGBP) announced today acceptance by the American Society for Hematology of a presentation by Christine Ichim, PhD, senior scientific research consultant to Regen BioPharma, at its annual meeting entitled "NR2F6 (EAR-2) Is a Novel Leukemia Oncogene Whose Cellular Function Is to Regulate Terminal Differentiation of Erythrocytes at the Proerythroblast Stage." The work will be presented on Saturday December 6, 2014 at the West Building, Level 1 in the Moscone Center, San Francisco at 5:30 PM.
Regen BioPharma Acquires University of Toronto Cancer Stem Cell Intellectual Property
Marketwired - Tue Nov 25, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) announced today acquisition of patent application # US 13/652,395 with a priority date of November 2008 which covers a novel gene target essential for the survival of cancer stem cells. Inventors of the intellectual property on which this patent application was filed are University of Toronto Hematologist Dr. Richard Wells and Dr. Christine Ichim, Senior Research Consultant for Regen BioPharma.
FDA Issues IND Number for Regen BioPharma's dCellVax Therapeutic Application, a Proposed Treatment for Breast Cancer
Marketwired - Tue Nov 04, 7:31AM CST
Regen BioPharma, Inc. (OTCBB: RGBP) announced today issuance of IND (Investigational New Drug Application) number 16200 from the FDA for a proposed Phase I/II clinical trial assessing safety with signals of efficacy of the dCellVax gene silenced dendritic cell immunotherapy for treating breast cancer.
Regen BioPharma's Chief Scientific Officer Examines Potential Role of Immunotherapeutic Treatment for Ebola in Conjunction With Other Current Therapies
Marketwired - Tue Oct 28, 8:05AM CDT
Regen BioPharma Inc.'s (OTCBB: RGBP) Chief Scientific Officer Dr. Thomas Ichim stated today that The Company is currently identifying potential immunotherapeutic treatments that might have value in treating some of the effects of Ebola in conjunction with other treatments. The goal of using immunotherapy in mitigating some of the side effects of Ebola is to jump start the body's own immune system to identify and fight off these potentially fatal conditions.
Regen BioPharma Inc. Files IND Application With FDA for dCellVax Breast Cancer Immune Therapy
Marketwired - Wed Oct 08, 11:29AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) announced today the filing of an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) to initiate a clinical trial assessing safety and therapeutic effects of dCellVax in patients with metastatic breast cancer. dCellVax is an immunotherapeutic product that utilizes the patient's own immune cells to attack the tumor. Success of dCellVax in the proposed trial is anticipated to pave the way for expanded use of dCellVax in a variety of other tumors. Advantages of cancer immune therapies include: a) lack of toxicity; b) ability to attack tumor metastasis; and c) generation of immunological memory, which protects the body from recurrence of the tumor.
Regenerative Medicine - Global Trends, Estimates and Forecasts, 2013-2019
M2 - Thu Apr 23, 9:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z5h992/regenerative) has announced the addition of the "Regenerative Medicine - Global Trends, Estimates and Forecasts, 2013-2019" report to their offering. Global Regenerative Medicine market is estimated to reach US$24.7 billion by 2017. Regenerative Medicine in Orthopedics market is projected to reach US$10.3 billion by 2017, growing at a CAGR of 12.2% for the analysis period 2013-2019 respectively. Skin/Integumentary and Urology together account for approximately 25.97% (2016) of the market are expected to support the Regenerative Medicine Industry going forward. Geographical analysis for Regenerative Medicine in Cardiology shows that the highest Compounded Annual Growth Rate (CAGR) of 18.1% is anticipated from Asia-Pacific region during the analysis period 2013-2019. The report Regenerative Medicine - Global Trends, Estimates and Forecasts, 2013-2019' reviews the latest trends in regenerative medicine with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for healthcare sector investments. The study reveals profitable investment strategies for market start-ups, pharmaceutical/biotechnology companies, laboratories, Contract/Clinical/Commercial Research Organizations (CROs), government/academic organizations, consulting firms, database buyers and many more in preferred locations. Regenerative Medicine - Segmentation - Therapeutic Area - Orthopedics - Skin/Integumentary - Cardiology - Neurology - Urology - Other - Biological Substitutes - Cells and Biomaterials - Biomolecules - Manufacturing Factors and - Other Companies Mentioned The Americas - Cell2B (USA) - Angiocrine Bioscience (USA) - Platelet Biogenesis (USA) - Biomatrica, Inc (USA) - Athersys, Inc. (USA) - Cellular Dynamics International, Inc. (USA) - Tengion Inc (USA) - Vericel Corporation (USA) - Wright Medical Technology (USA) - Tissuegene, Inc. (USA) - Shire Regenerative Medicine (USA) - Regen Biopharma (Bio-Matrix Scientific Group) (USA) - Dsm Biomedical (USA) - Harvard Apparatus Regenerative Technology (USA) Europe - Cellserve Gmbh (Germany) - Trakcel Ltd (United Kingdom) - Crispr Therapeutics (Switzerland) Asia-Pacific - Cytori Therapeutics Inc (Japan) - Cyfuse Biomedical Kk (Japan) - Regenovo Biotechnology (China) - Cynata Therapeutics Limited (Australia) For more information visit http://www.researchandmarkets.com/research/z5...generative
VCEL: 2.12 (-0.01), ICEL: 16.55 (+0.03), CYTX: 1.99 (-0.02), ATHX: 2.13 (-0.02)
Regen BioPharma Scheduled to Make Presentation at American Society for Hematology's 56th Annual Meeting in San Francisco December 6th - 9th
Marketwired - Mon Dec 01, 7:30AM CST
Regen BioPharma (OTCBB: RGBP) announced today acceptance by the American Society for Hematology of a presentation by Christine Ichim, PhD, senior scientific research consultant to Regen BioPharma, at its annual meeting entitled "NR2F6 (EAR-2) Is a Novel Leukemia Oncogene Whose Cellular Function Is to Regulate Terminal Differentiation of Erythrocytes at the Proerythroblast Stage." The work will be presented on Saturday December 6, 2014 at the West Building, Level 1 in the Moscone Center, San Francisco at 5:30 PM.
Regen BioPharma Acquires University of Toronto Cancer Stem Cell Intellectual Property
Marketwired - Tue Nov 25, 7:30AM CST
Regen BioPharma Inc. (OTCBB: RGBP) announced today acquisition of patent application # US 13/652,395 with a priority date of November 2008 which covers a novel gene target essential for the survival of cancer stem cells. Inventors of the intellectual property on which this patent application was filed are University of Toronto Hematologist Dr. Richard Wells and Dr. Christine Ichim, Senior Research Consultant for Regen BioPharma.
FDA Issues IND Number for Regen BioPharma's dCellVax Therapeutic Application, a Proposed Treatment for Breast Cancer
Marketwired - Tue Nov 04, 7:31AM CST
Regen BioPharma, Inc. (OTCBB: RGBP) announced today issuance of IND (Investigational New Drug Application) number 16200 from the FDA for a proposed Phase I/II clinical trial assessing safety with signals of efficacy of the dCellVax gene silenced dendritic cell immunotherapy for treating breast cancer.
Regen BioPharma's Chief Scientific Officer Examines Potential Role of Immunotherapeutic Treatment for Ebola in Conjunction With Other Current Therapies
Marketwired - Tue Oct 28, 8:05AM CDT
Regen BioPharma Inc.'s (OTCBB: RGBP) Chief Scientific Officer Dr. Thomas Ichim stated today that The Company is currently identifying potential immunotherapeutic treatments that might have value in treating some of the effects of Ebola in conjunction with other treatments. The goal of using immunotherapy in mitigating some of the side effects of Ebola is to jump start the body's own immune system to identify and fight off these potentially fatal conditions.
Regen BioPharma Inc. Files IND Application With FDA for dCellVax Breast Cancer Immune Therapy
Marketwired - Wed Oct 08, 11:29AM CDT
Regen BioPharma Inc. (OTCBB: RGBP) announced today the filing of an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) to initiate a clinical trial assessing safety and therapeutic effects of dCellVax in patients with metastatic breast cancer. dCellVax is an immunotherapeutic product that utilizes the patient's own immune cells to attack the tumor. Success of dCellVax in the proposed trial is anticipated to pave the way for expanded use of dCellVax in a variety of other tumors. Advantages of cancer immune therapies include: a) lack of toxicity; b) ability to attack tumor metastasis; and c) generation of immunological memory, which protects the body from recurrence of the tumor.
